<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2794-1140</journal-id>
<journal-title><![CDATA[Pharmaceutical Care España]]></journal-title>
<abbrev-journal-title><![CDATA[Pharm Care Esp.]]></abbrev-journal-title>
<issn>2794-1140</issn>
<publisher>
<publisher-name><![CDATA[Fundación Pharmaceutical Care España]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2794-11402025000101402</article-id>
<article-id pub-id-type="doi">10.60103/phc.v27.e891</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Descontinuación del tratamiento con benzodiacepinas de una paciente mediante Gestión Integral de la Medicación en Farmacia Comunitaria]]></article-title>
<article-title xml:lang="en"><![CDATA[Benzodiazepine Tapering in a Community Pharmacy Setting: A Case Managed Through Comprehensive Medication Management]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sogorb]]></surname>
<given-names><![CDATA[María Albert]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González Valdivieso]]></surname>
<given-names><![CDATA[María]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Calvo Martínez]]></surname>
<given-names><![CDATA[Andrea]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Verdú Calvo]]></surname>
<given-names><![CDATA[Jorge]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Unidad de Optimización de la Farmacoterapia en Farmacia La Barbera  ]]></institution>
<addr-line><![CDATA[La Vila Joiosa (Alicante) ]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2025</year>
</pub-date>
<volume>27</volume>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S2794-11402025000101402&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S2794-11402025000101402&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S2794-11402025000101402&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN Mujer de 36 años con insomnio, dolor secundario a espondilolistesis lumbar de grado 3 y antecedentes de ansiedad. Su farmacoterapia incluye benzodiacepinas, amitriptilina, tramadol/paracetamol, bromuro de otilonio, betahistina y melatonina. A petición de la paciente, se diseñó un plan para la retirada gradual de benzodiacepinas que se basó en la conversión a diazepam, estabilización y una reducción progresiva siguiendo guías clínicas, dentro del marco de la Gestión Integral de la Medicación. Este caso destaca la importancia de la visión biopsicosocial durante el acompañamiento farmacoterapéutico a personas que usan benzodiacepinas de manera crónica, evaluando alternativas consensuadas y minimizando efectos adversos durante la retirada. La colaboración entre Farmacia Comunitaria y Atención Primaria facilita las intervenciones personalizadas, logrando objetivos terapéuticos y mejorando la calidad de vida de la paciente.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT A 36-year-old woman with insomnia, pain secondary to grade 3 lumbar spondylolisthesis and a history of anxiety. Her pharmacotherapy includes benzodiazepines, amitriptyline, tramadol/paracetamol, otilonium bromide, betahistine and melatonin. At the patient's request, a gradual benzodiazepine withdrawal plan was designed, based on conversion to diazepam, stabilization and a progressive dose reduction following clinical guidelines, within the framework of Comprehensive Medication Management. This case highlights the importance of a biopsychosocial approach in pharmaceutical care for patients using benzodiazepines chronically, evaluating agreed-upon alternatives and minimizing adverse effects during tapering. Collaboration between Community Pharmacy and Primary Care facilitates personalized interventions, achieving therapeutic goals and improving the patient's quality of life.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Benzodiazepinas]]></kwd>
<kwd lng="es"><![CDATA[Deshabituación]]></kwd>
<kwd lng="es"><![CDATA[Reducción gradual de fármacos]]></kwd>
<kwd lng="es"><![CDATA[Gestión Integral de la medicación]]></kwd>
<kwd lng="es"><![CDATA[Optimización de la farmacoterapia]]></kwd>
<kwd lng="en"><![CDATA[Benzodiazepines]]></kwd>
<kwd lng="en"><![CDATA[Drug Tapering]]></kwd>
<kwd lng="en"><![CDATA[Drug Withdrawal]]></kwd>
<kwd lng="en"><![CDATA[Comprehensive Medication Management]]></kwd>
<kwd lng="en"><![CDATA[Optimization]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cipolle]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Strand]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Morley]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Pharmaceutical Care Practice. The Patient Centered Approach to Medication Management]]></source>
<year>2012</year>
<edition>Third</edition>
<publisher-loc><![CDATA[New York ]]></publisher-loc>
<publisher-name><![CDATA[McGraw-Hill companies]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Picton]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Wright]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<source><![CDATA[Medicines Optimisation: Helping patients make the most of their medicines]]></source>
<year>2013</year>
<publisher-name><![CDATA[Royal Pharmaceutical Society]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pérez Rodríguez]]></surname>
<given-names><![CDATA[RO]]></given-names>
</name>
<name>
<surname><![CDATA[González Valdivieso]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Silva-Castro]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Entrevistas en profundidad: técnica complementaria a las entrevistas clínicas en las intervenciones basadas en necesidades del paciente]]></article-title>
<source><![CDATA[Pharm Care Esp]]></source>
<year>2021</year>
<volume>23</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>34-41</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ashton]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<source><![CDATA[Benzodiazepines: How They Work and How to Withdraw (The Ashton Manual)]]></source>
<year>2002</year>
<publisher-loc><![CDATA[Newcastle ]]></publisher-loc>
<publisher-name><![CDATA[University of Newcastle]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brandt]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Garber]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Gallimore]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gudbranson]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Fuentes]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kondo]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prescribing and deprescribing guidance for benzodiazepine and benzodiazepine receptor agonist use in adults with depression, anxiety, and insomnia: an international scoping review]]></article-title>
<source><![CDATA[eClinicalMedicine]]></source>
<year>2024</year>
<volume>70</volume>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
